Insulet Q3 revenue +26% to $543.9M; beats guidance; raises FY outlook; Omnipod 5 cleared for type 2 diabetes

INSULET CORP

2024-Q3 EPS reported $4.40 revenue$1,474,100,000

Revenue $543.9M (+25.7% YoY); Omnipod $533.6M (+26.4%); U.S. +23.4%, International +36.1%.
GAAP net income $77.5M ($1.08 EPS) vs $51.9M ($0.74); adjusted net income $64.2M ($0.90 EPS).
Gross margin 69.3% (+150bps); operating income $88.1M (16.2% of revenue); adjusted EBITDA $126.1M (23.2%).
Received FDA clearance for Omnipod 5 for type 2 diabetes; first AID system for both T1 and T2.
Raised full-year revenue and margin guidance; Q3 revenue exceeded high end of 21% constant currency guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.